Grégory Strabach

Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women

Walter Krauwinkel, Jan van Dijk, Marloes Schaddelee et al. · Clinical Therapeutics · 2012 · 96 citations

Medicine, Pharmacokinetics, Pharmacology +7

The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol

Walter Krauwinkel, James Dickinson, Marloes Schaddelee et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2013 · 46 citations

Medicine, Pharmacokinetics, Pharmacology +7

Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH‐impedance study in healthy subjects

Frank Zerbib, Charlotte Keywood, Grégory Strabach · Neurogastroenterology & Motility · 2010 · 44 citations

Medicine, Pharmacokinetics, Pharmacology +15

Evaluation of the Pharmacokinetic Interaction Between the β₃‐Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects

Walter Krauwinkel, Virginie Kerbusch, John Meijer et al. · Clinical Pharmacology in Drug Development · 2013 · 17 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +15

YM150, An Oral Direct Inhibitor of Factor Xa, Demonstrated a Predictable and Dose-Proportional Pharmacokinetic/Pharmacodynamic Profile After Single and Multiple Dosing: Results From Three Studies

Dorien Groenendaal‐van de Meent, Marten Heeringa, Takeshi Kadokura et al. · Blood · 2010 · 16 citations

Pharmacy, Pharmacokinetics, Pharmacology +10